vimarsana.com
Home
Live Updates
Castle Biosciences Reports First Quarter 2024 Results : vima
Castle Biosciences Reports First Quarter 2024 Results : vima
Castle Biosciences Reports First Quarter 2024 Results
Q1 2024 revenue increased 74% over Q1 2023 to $73 million
Q1 2024 total test reports increased 40% over Q1 2023
Raising full-year 2024 revenue guidance to $255-265 million from $235-240...
Related Keywords
United States ,
Israel ,
Russia ,
Ukraine ,
American ,
Castle Biosciences ,
Derek Maetzold ,
Program Registries ,
Mental Health ,
See The Company ,
Instagram ,
Securities Exchange ,
Facebook ,
Castle Biosciences Inc ,
National Cancer Institute Surveillance ,
Linkedin ,
Nasdaq ,
National Comprehensive Cancer Network ,
American Joint Committee On Cancer Staging Manual ,
Medicare Contractors ,
Decisiondx Melanoma Class ,
Quarter Ended March ,
Path Melanoma ,
Adjusted Gross Margin ,
Cash Equivalents ,
Marketable Investment ,
Recent Accomplishments ,
American Joint Committee ,
Cancer Staging Manual ,
National Cancer Institute ,
End Results ,
Investor Relations ,
Adjusted Revenues ,
Gross Margin ,
Adjusted Gross ,
Mypath Melanoma ,
Securities Act ,
Securities Exchange Act ,
Israel Hamas War ,
Tissuecypher Test ,
Annual Report ,
Quarterly Report ,
Markets ,